Generic Name and Formulations:
Tazarotene 0.1%; foam.
Stiefel Laboratories, Inc.
Cleanse and dry affected area. Apply a thin layer to affected areas on face and/or upper trunk once daily in the PM. Women of childbearing potential: begin therapy during normal menses.
Obtain reliable negative pregnancy test within 2 weeks before starting therapy; use effective contraception during therapy. Do not use on broken or eczematous skin. History of local hypersensitivity. Photosensitivity. History of skin cancer. Avoid eyes, lips, mouth, mucous membranes, sun and UV light; use adequate sun protection. Increased irritation in extreme weather. Discontinue if excessive local irritation occurs. Flammable. Nursing mothers: not recommended.
Cumulative irritant effect with concomitant other topical acne therapy; use caution. Avoid use until the effects of strong topical drying agents have subsided. Concomitant oxidizing agents (eg, benzoyl peroxide) may cause tazarotene degradation and reduce efficacy; apply at different times of the day (eg, AM & PM) if combination treatment is needed.
Application site reactions (eg, irritation, dryness, erythema, exfoliation, pain, photosensitivity, pruritus, dermatitis).
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...